Saxagliptin ( Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Med Lett Drugs Ther. 2009 Nov 2; 51(1324):85-6
Saxagliptin ( Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Paliperidone palmitate ( Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release…
Med Lett Drugs Ther. 2009 Nov 2; 51(1324):88
Paliperidone palmitate ( Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006. 1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen. 2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal) , which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better choice for long-term treatment of schizophrenia than a first-generation drug such as haloperidol, which can also be injected once a month and costs much less. 4 1. Paliperidone (Invega) for schizophrenia. Med Lett Drugs Ther 2007; 49:21. 2. JC West et al. Use of depot antipsychotic medications for medication non-adherence in schizophrenia. Schizophr Bull 2008; 34:995. 3. D Hough et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1022. 4. Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35. Download: U.S. English
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax , two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting…
Med Lett Drugs Ther. 2009 Nov 2; 51(1324):88
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax , two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old. Hiberix can also be given to children 12-15 months old as a scheduled booster dose. 1 1. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:1008. Download: U.S. English